In a 77‑year‑old man with Gleason 9 prostate cancer with lymph node and seminal vesicle involvement undergoing definitive radiation therapy and androgen‑deprivation therapy, when should abiraterone (Zytiga) be initiated?

Timing of Abiraterone in High-Risk Prostate Cancer with Radiation and ADT

Start abiraterone acetate 1000 mg daily with prednisone 5 mg daily concurrently at the initiation of radiation therapy and ADT, continuing for 2 years. 1

Definitive Recommendation

For this 77-year-old patient with Gleason 9 prostate cancer with lymph node and seminal vesicle involvement (cN1M0 disease), the European Association of Urology (EAU) 2024 guidelines provide a strong recommendation to offer IMRT/VMAT plus IGRT to the prostate plus pelvis in combination with long-term ADT (2-3 years) and 2 years of abiraterone for cN1M0 patients. 1

Treatment Algorithm

Immediate Initiation (Concurrent with RT and ADT):

• Start all three therapies together: radiation therapy, ADT, and abiraterone acetate plus prednisone 1
• Abiraterone dosing: 1000 mg daily (taken on empty stomach, at least 1 hour before or 2 hours after food) with prednisone 5 mg daily 1
• Duration of abiraterone: Continue for 2 years 1, 2
• Duration of ADT: Continue for 2-3 years (long-term) 1

Evidence Basis:

The NCCN 2023 guidelines classify abiraterone with ADT as a category 1 (highest level of evidence) preferred option for high-risk disease. 1 This recommendation is based primarily on the STAMPEDE and LATITUDE trials, which demonstrated:

• Overall survival benefit: HR 0.63 (95% CI 0.5-0.76, P<0.0001) in the overall STAMPEDE population 1
• Metastasis-free survival: HR 0.53 (95% CI 0.44-0.64, p<0.0001) at 6 years (82% vs 69%) 2
• Prostate cancer-specific survival: HR 0.49 (95% CI 0.37-0.65, p<0.0001) 2

The STAMPEDE trial specifically included node-positive (N1) patients like your case, showing consistent benefit across all subgroups including N1M0 disease (HR 0.29 for failure-free survival). 1, 2

Critical Monitoring Requirements

Mandatory monitoring during abiraterone therapy:

• Blood pressure: Monitor closely for hypertension (grade 3+ hypertension occurred in 5-14% of patients) 2
• Liver function tests: Check regularly for transaminitis (grade 3+ ALT elevation in 6-13% of patients) 2
• Electrolytes: Monitor potassium for hypokalemia due to mineralocorticoid excess 1, 2
• Cardiac function: Watch for cardiac events, particularly in elderly patients 1

Age-Related Considerations:

At age 77, this patient falls into the older age group where STAMPEDE showed increased toxicities (grade 3-5 adverse events 47% vs 33% in younger patients). 1 However, the survival benefit remains substantial, and the strong guideline recommendation applies regardless of age. 1

Common Pitfalls to Avoid

• Do not delay abiraterone initiation: The trials showing survival benefit used concurrent initiation with ADT and RT, not sequential therapy 1, 2
• Do not omit prednisone: Prednisone 5 mg daily is mandatory to mitigate mineralocorticoid excess from CYP17 inhibition 1
• Do not use shorter duration: The 2-year duration of abiraterone is evidence-based for N1M0 disease 1, 2
• Do not skip pelvic nodal radiation: With N1 disease, whole pelvic RT is indicated in addition to prostate radiation 1

Alternative Dosing Option

An alternative lower-cost option is abiraterone 250 mg daily taken with a low-fat breakfast (instead of 1000 mg fasting), which provides equivalent bioavailability and may improve adherence. 1 This is a category 2B recommendation. 1